Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in Biosimilars dealmaking
2.1. Introduction
2.2. Biosimilars partnering over the years
2.3. Most active Biosimilars dealmakers
2.4. Biosimilars partnering by deal type
2.5. Biosimilars partnering by therapy area
2.6. Biosimilars partnering by industry sector
2.7. Deal terms for Biosimilars partnering
2.7.1 Biosimilars partnering headline values
2.7.2 Biosimilars deal upfront payments
2.7.3 Biosimilars deal milestone payments
2.7.4 Biosimilars royalty rates
2.8. The anatomy of an Biosimilars deal
2.8. a. Case study 1: RRD International & Dipexium Pharmaceuticals
2.8.b. Case study 2: Hospira & Cempra Pharmaceutical
2.8.c. Case study 3: Astellas & Optimer Pharmaceuticals

Chapter 3 – Leading Biosimilars deals
3.1. Introduction
3.2. Top Biosimilars deals by value

Chapter 4 – Most active Biosimilars dealmakers
4.1. Introduction
4.2. Most active Biosimilars dealmakers
4.3. Most active Biosimilars partnering company profiles

Chapter 5 – Biosimilars contracts dealmaking directory
5.1. Introduction
5.2. Biosimilars contracts dealmaking directory

Chapter 6 – Biosimilars dealmaking by technology type

Chapter 7 – Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

Appendices
Appendix 1 – Biosimilars deals by company A-Z
Appendix 2 – Biosimilars deals by stage of development
Appendix 3 – Biosimilars deals by deal type
Appendix 4 – Biosimilars deals by therapy area
Appendix 5 –Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from Current Partnering

Table of figures
Figure 1: Biosimilars partnering since 2010
Figure 2: Active Biosimilars dealmaking activity sincce 2010
Figure 3: Biosimilars partnering by deal type since 2010
Figure 4: Biosimilars partnering by disease type since 2010
Figure 5: Biosimilars partnering by industry sector since 2010
Figure 6: Biosimilars deals with a headline value
Figure 7: Biosimilars deals with an upfront value
Figure 8: Biosimilars deals with a milestone value
Figure 9: Biosimilars deals with a royalty rate value
Figure 10: Top Biosimilars deals by value since 2010
Figure 11: Most active Biosimilars dealmakers since 2010
Figure 12: Biosimilars partnering by technology type since 2010
Figure 13: Online partnering resources
Figure 14: Forthcoming partnering events

Companies mentioned
3SBio, Abbvie, Abreos Biosciences, Abzena, Accord Healthcare, Aceno Biotherapeutics, AdAlta, AET Biotech, Aetos Biologics, AffaMed Therapeutics, Agila Specialties, AIT Bioscience, Algorithme Pharma Holdings, Alteogen, Altiora, Alvogen, Alvotech, Amedica, Amgen, Amneal Pharmaceuticals, Avid Bioservices, Back-A-Line, Bacterin International, Baxter International, Bio-Thera Solutions, Biocnd, Biocon, Bioeq IP, Bio Farma, Biogen, Biooutsource, BioSavita, BioSciencesCorp, Bioton, BioXpress, Boehringer Ingelheim, Boston Oncology, Bruker, C-Bridge Capital, Catalent, CEA-Leti, Celares, Celerion, Cellectis, Celltrion, Chemo Sa Lugano, Chungnam National University, Cipla, CJ Corp, Clinigen, Cobra Biologics, Coherus Biosciences, Compass Biotechnologies, Concord Biosciences, Cook Pharmica, CR Pharma, Daiichi Sankyo, Diabeloop, DM Corporation, Dr. Reddy’s Laboratories, Dyadic International, EirGenix, EMD Millipore, Epirus Biopharmaceuticals, Epivax, European Commission, Evercyte, Evotec, Ewopharma, Formycon, Fujifilm, Fujifilm Kyowa Kirin Biologics, Fuji Pharma, GC Pharma, Gedeon Richter, GE Healthcare, Genentech, Genhelix Biopharmaceutical, Genor Biopharma, Hadasit Medical Research Services and Development, Hanwha Chemical, Helvetic Biopharma, Henlius Biotech, Hikma Pharmaceuticals, Hoffmann La Roche, Horizon 2020, Hospira, Innovent Biologics, inVentiv Health, Ipca Laboratories, Ipsen, Jacobson Pharma, JAMP Pharma Group, JHL Biotech, Kamada, Karolinska Institute, Kymos Pharma Services, Kyowa Hakko Kirin, Laboratorios Liomont, LABORATORIOS SAVAL, Ligacept, Livzon Mabpharm, Lupin, M+W Group, Mab-Venture Biopharma, Mabion, mAbXience, Medicago, Medipolis, Merck and Co, Merck BioVentures, Merck KGaA, Merck Serono, MGC Diagnostics, Ministry of Health (Brazil), Mithra Pharmaceuticals, Mitsubishi Chemical, Mochida Pharmaceutical, Momenta Pharmaceuticals, Mundipharma, Mylan Laboratories, Mylan Pharmaceuticals, Nan Fung Group, NanoLock, Natco Pharmaceuticals, National Cancer Institute, NCPC GeneTech, NeuClone, Novo Nordisk, Oncobiologics, ORF Genetics, Orox Pharmaceuticals, Orygen Biotecnologia, Pall Corporation, Pangen Biotech, Parexel, PBS Biotech, Perfinity Biosciences, Pfenex, Pfizer, PharmaPraxis, PlantForm, Polpharma, PPD, PRA Health Sciences, Premier Inc, Premier Research, Prestige BioPharma, ProBioGen, Qilu Pharmaceutical, Quanta BioDesign, QuiaPEG Pharmaceuticals, R-Pharm, Ranbaxy Laboratories, Revance Therapeutics, Samsung Bioepis, Samsung Biologics, Sandoz, Sanofi, Santo Holding, Scottish Government, Selexis, Serum Institute of India, Simcere Pharmaceuticals, Spectrum Pharmaceuticals, SQI Diagnostics, STADA Arzneimittel, STC Biologics, Stelis Biopharma, Strides Arcolab, Synthon, TetraLogic Pharmaceuticals, Teva Pharmaceutical Industries, Theradiag, Toyota Tsusho, TR-Pharm, True Diagnostics, TS Dyne, Turgut Ilaclari, UGA Biopharma, UMN Pharma, Univercells, Vcell Healthcare, Vela Laboratories, Viropro, Walloon Region Investment Fund, Walter and Eliza Hall Institute, Watson Pharmaceuticals, Xbrane Bioscience, Xcellerex, Xencor, XL-Protein, Yas Holding, YL Biologics, Yoshindo, Zhejiang Hisun Pharmaceutical, Zhejiang Huahai Pharmaceutical, Zosano Pharma